Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Different D-Dimer Values Compared for Venous Thromboembolism Risk

By LabMedica International staff writers
Posted on 27 Sep 2015
D-dimer assays are generally evaluated according to cutoff points calibrated for of venous thromboembolism (VTE) exclusion and used to estimate the individual risk of recurrence after a first idiopathic event VTE.

The increase in age-dependent D-dimer levels has long been seen as a problem for the use of these assays in the work-up for VTE exclusion, and the assays performs poorly in the elderly population when traditional cutoff levels are adopted. More...
Different cutoff systems have therefore been proposed and prospectively investigated to rule out pulmonary embolism.

Scientist at the University Hospital of Bologna (Italy) and their colleagues screened a total of 1,010 patients, whose index VTE event was idiopathic or associated with weak risk factors, and were included in the management protocol. Persistently negative D-dimer results were recorded in 528 patients (52.8%) who permanently interrupted anticoagulation and were followed up for a maximum of two years. In contrast, the remaining 482 patients had positive D-dimer results, and at the moment of their first positive result, were recommended to continue or resume anticoagulant therapy and followed by their anticoagulation clinic.

D-dimer levels were measured using the following commercial quantitative assays: VIDAS D-dimer Exclusion (bioMerieux; Lyon, France), Innovance D-DIMER (Siemens; Deerfield, IL, USA), HemosIL D-dimer HS or HemosIL D-dimer (Instrumentation Laboratory; Milan, Italy), and (v) STA Liatest D-dimer (DiagnosticaStago; Asnieres-sur-Seine, France). As cutoff values for negative/positive results, the centers used those specific for the assay, distinguishing those with results expressed as fibrinogen equivalent units (FEU) or non-FEU (D-dimer units) and for age and gender.

The predetermined cutoff levels for each assay, specific for age (lower in subjects less than 70 years), and gender (because it is lower in males), were used. In young subjects, the D-dimer-ULtrasonography in Combination Italian Study (DULCIS) low cutoff levels resulted in half the recurrent events that would have occurred using the other criteria. In elderly patients the DULCIS results were similar to those calculated for the two age-adjusted criteria. The adoption of traditional VTE exclusion criteria would have led to positive results in the large majority of elderly subjects without a significant reduction in the rate of recurrent event.

The authors concluded that the low cutoff levels adopted in the DULCIS study for young subjects resulted in more young patients who resumed anticoagulation with subsequent increased protection from recurrent events in this population that is at high risk of recurrence. In elderly patients, the high DULCIS cutoff points led to results similar to those calculated for the two age-adjusted criteria; the adoption of VTE exclusion criteria would have led to positive results in the large majority of subjects, without a significant reduction in the rate of recurrent event. The study was published on September 12, 2015, in the journal International Journal of Laboratory Hematology.

Related Links:

University Hospital of Bologna
bioMérieux
Siemens



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.